Subtyping of advanced lung cancer based on PD-L1 expression, tumor histopathology and mutation burden (EGFR and KRAS): a study from North India

Immune checkpoint inhibitor (PD-L1) therapy of advanced non-small-cell lung cancer (NSCLC) has variable outcomes. Tumor subtypes based on PD-L1 expression, histopathology, mutation burden is required for patient stratification and formulation of treatment guidelines. Lung cancers (n=57) diagnosed at...

Full description

Bibliographic Details

Published in:	Monaldi archives for chest disease Vol. 93; no. 4
Main Authors:	Kulshrestha, Ritu, Saxena, Himanshi, Kumar, Raj, Spalgius, Sonam, Mrigpuri, Parul, Goel, Nitin, Menon, Balakrishnan, Rani, Meenu, Mahor, Pawan, Bhutani, Ishita
Format:	Journal Article
Language:	English
Published:	Italy PAGEPress Publications 01.02.2023
Subjects:	Subtyping-lung cancer, PD-L1, coexisting EGFR/KRAS mutations, tumour histopathology, North India
ISSN:	1122-0643, 2532-5264, 2532-5264
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!